Jessica B Casaletto et al.
Proceedings of the National Academy of Sciences of the United States of America, 116(15), 7533-7542 (2019-03-23)
Activation of the Met receptor tyrosine kinase, either by its ligand, hepatocyte growth factor (HGF), or via ligand-independent mechanisms, such as MET amplification or receptor overexpression, has been implicated in driving tumor proliferation, metastasis, and resistance to therapy. Clinical development